Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov 15;51(10):1201-8.
doi: 10.1086/656624. Epub 2010 Oct 18.

Review of hepatitis B therapeutics

Debika Bhattacharya  1 , Chloe L Thio
Affiliations
Review

Review of hepatitis B therapeutics

Debika Bhattacharya et al. Clin Infect Dis. .

Abstract

Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest: All authors: no conflicts

Figures

Figure 1
Figure 1
Life cycle of hepatitis B virus (HBV). Reprinted from Rehermann and Nascimbeni [3], with permission from the Nature Publishing Group. cccDNA, covalently closed circular DNA; ER, endoplasmic reticulum; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBx, HBVX protein; mRNA, messenger RNA; POL, polymerase.
Figure 2
Figure 2
Potency and emergence of resistance. Reprinted from Soriano et al [55], with permission from Wolters Kluwer Health. ADV. adefovir; ETV, entecavir; FTC, emtricitabine; IFN, interferon; LAM, lamivudine; LdT, telbivudine; TDF, tenofovir.
See this image and copyright information in PMC

References

    1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500. - PubMed
    1. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol. 2010;52:282–4. - PubMed
    1. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–21. - PubMed

    1. Pegasys. [package insert]. Nutley, NJ 2002;Hoffmann-La Roche.

    1. Cooksley WGE, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298–305. - PubMed

Publication types

MeSH terms